536 related articles for article (PubMed ID: 32755220)
21. Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
Viana PCC; Horvat N; do Santos VR; Lima TC; Romão DDS; Cerri LMO; de Castro MG; Vargas HA; Miranda JA; Leite CDC; Cerri GG
Int Braz J Urol; 2019; 45(4):724-731. PubMed ID: 31136114
[TBL] [Abstract][Full Text] [Related]
22. Comparison between
Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B
Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
[TBL] [Abstract][Full Text] [Related]
23. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Performance and Interobserver Consistency of the Prostate Imaging Reporting and Data System Version 2: A Study on Six Prostate Radiologists with Different Experiences from Half a Year to 17 Years.
Ke Z; Wang L; Min XD; Feng ZY; Kang Z; Zhang PP; Li BS; You HJ; Hou SC
Chin Med J (Engl); 2018 Jul; 131(14):1666-1673. PubMed ID: 29998885
[TBL] [Abstract][Full Text] [Related]
25. Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.
Becker AS; Cornelius A; Reiner CS; Stocker D; Ulbrich EJ; Barth BK; Mortezavi A; Eberli D; Donati OF
Eur J Radiol; 2017 Sep; 94():58-63. PubMed ID: 28941761
[TBL] [Abstract][Full Text] [Related]
26. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
Chen F; Cen S; Palmer S
Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
[TBL] [Abstract][Full Text] [Related]
27. A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.
Giannarini G; Girometti R; Crestani A; Rossanese M; Calandriello M; Cereser L; Bednarova S; Battistella C; Sioletic S; Zuiani C; Valotto C; Ficarra V
Urology; 2019 Jan; 123():191-197. PubMed ID: 30273613
[TBL] [Abstract][Full Text] [Related]
28. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
29. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
30. Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
Wang J; Wu CJ; Bao ML; Zhang J; Wang XN; Zhang YD
Eur Radiol; 2017 Oct; 27(10):4082-4090. PubMed ID: 28374077
[TBL] [Abstract][Full Text] [Related]
31. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
32. Interobserver Agreement and Positivity of PI-RADS Version 2 Among Radiologists with Different Levels of Experience.
Mussi TC; Yamauchi FI; Tridente CF; Tachibana A; Tonso VM; Recchimuzzi DR; de Souza Leão LR; Luz DC; Martins T; Baroni RH
Acad Radiol; 2019 Aug; 26(8):1017-1022. PubMed ID: 30268722
[TBL] [Abstract][Full Text] [Related]
33. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Prostate Imaging and Reporting Data System V2.0 and V2.1 for Evaluation of Transition Zone Lesions: A 5-Reader 202-Patient Analysis.
Kim N; Kim S; Prabhu V; Shanbhogue K; Smereka P; Tong A; Anthopolos R; Taneja SS; Rosenkrantz AB
J Comput Assist Tomogr; 2022 Jul-Aug 01; 46(4):523-529. PubMed ID: 35405714
[TBL] [Abstract][Full Text] [Related]
36. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.
Wang X; Bao J; Ping X; Hu C; Hou J; Dong F; Guo L
Oncol Lett; 2018 Sep; 16(3):3201-3206. PubMed ID: 30127915
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
40. Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis.
Wu M; Krishna S; Thornhill RE; Flood TA; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Sep; 50(3):940-950. PubMed ID: 30701625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
